Repurposing minocycline to target FOXA1 and its mutants in prostate Cancer.

doi:10.1016/j.cellsig.2026.112843

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Repurposing minocycline to target FOXA1 and its mutants in prostate Cancer.

Cellular signalling - 1 Dec 2026

Zhang Ziyin, Xu Jingwen, Zang Kai, Zhang Yingshuang, Liu Zhihao, Song Yuxuan, He Shaoya, He Yundong

Abstract excerpt

FOXA1 and the androgen receptor (AR) are essential for prostate cancer cell survival. Although current targeted therapies against AR are widely used, they frequently lead to drug resistance, partly due to alterations in FOXA1. Minocycline, a commonly prescribed antibiotic, has demonstrated anticancer properties; however, its functional impact on FOXA1 and AR signaling remains unclear. In this study, we...

Read the complete abstract on PubMed

Topics

Male
Hepatocyte Nuclear Factor 3-alpha
Minocycline
Humans
Prostatic Neoplasms
Animals
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Cell Line, Tumor

Receptors, Androgen

Mice

Drug Repositioning

Signal Transduction

Cell Proliferation

Mice, Nude

Source

Open in PubMed

Identifiers

PMID: 42636948
DOI: 10.1016/j.cellsig.2026.112843

Genes

FOXA1
AR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Repurposing minocycline to target FOXA1 and its mutants in prostate Cancer.PMID 42636948Read ↗

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and AndrogenSemantic proximity Read ↗

Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatmentsSemantic proximity Read ↗

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read ↗

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.Semantic proximity Read ↗

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Semantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate CancerSemantic proximity Read ↗

Pioneer of prostate cancer: past, present and the future of FOXA1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.